Original Article

Access this article online
Quick Response Code:

Website:
www.carcinogenesis.com
DOI:
10.4103/jcar.jcar_22_01_16

Oncogenic Signaling Pathways in Carcinogenesis

Jane Austen[1], Emily Bronte[2]

Abstract

The aim of research into the complexities of oncogenic signaling pathways in carcinogenesis is dynamic and continuing. The discovery of targeted medicines and identifying important molecular actors have enormous potential to improve cancer outcomes. A new chapter in the battle against this terrible disease marked by the possibility of more individualized and efficient cancer treatment methods as our knowledge of these pathways grows. Numerous variables, such as prolonged exposure to carcinogens, persistent inflammation, and the activation of oncogenic signaling pathways, are responsible for this proliferation. Additional genetic and epigenetic alterations in promoted cells give them a growth advantage over neighboring normal cells. The hallmarks of cancer cells are persistent proliferation, evasion of growth regulators, and resistance to cell death, which are caused by dysregulation of these pathways. Furthermore, the complex interactions between cancer cells and the tumor microenvironment have a major impact on how carcinogenesis develops. Overall, the research found that carcinogenesis is a complex process defined by the progressive accumulation of genetic and epigenetic changes that give altered cells a growth advantage. Comprehending the molecular complexities involved in this process is essential for formulating efficacious approaches towards cancer prevention, early detection, and therapy, ultimately leading to enhanced results for cancer patients.

Keywords:

Oncogenic (O), Signaling Pathway (SP), Carcinogenesis (CC), smart PLS Algorithm.

Introduction

The Carcinogenesis, the difficult method through which normal cells change into harmful complements, lies at the heart of cancer biology. The ability of the fundamental molecular methods heavy this change is of chief importance for the growth of directed beneficial involvements and inhibition approaches [1]. Essential to carcinogenesis are oncogenic signing ways and complicated networks of molecular connections that control cellular procedures like differentiation, survival, and proliferation. These ways are central in helping unrestrained development, escaping apoptosis, and gaining invasive properties, all symbol structures of cancer, The word "oncogene" was firstly invented by Peyton Rous in 1911, and later, subsequently, our understanding of these dangerous genes and their signaling ways has significantly extended. Oncogenes are a set of genes that, when changed or aberrantly expressed , can affect the abandoned development and existence of cells, which is important to the growth of cancer [2]. The vast and intricate network of molecular processes known as oncogenic signaling pathways in carcinogenesis is responsible for the initiation and progression of cancer. The process by which healthy cells become cancerous is known as carcinogenesis, and it is a complex phenomenon impacted by a person's genetic makeup, lifestyle, and environment. To treat cancer, it is essential to comprehend the complex signaling mechanisms that underpin this transition to design targeted medications and interventions. Fundamentally, carcinogenesis results from abnormal biological processes that control proliferation, differentiating cells, and cell death.

A key factor in this dysregulation is the action of oncogenic signaling pathways,

[1] *Military Academy, University of Defense in Belgrade, Belgrade, Serbia.*
[2] *Department of Structural Analysis, Technical University of Berlin, Berlin, German.*

Address for correspondence:
Emily Bronte, Department of Structural Analysis, Technical University of Berlin, Berlin, German.

Submitted: 19-Dec-2022
Revised: 09-Jan-2023
Accepted: 29-Mar-2023
Published: 19-Apr-2023

How to cite this article: Austen J, Bronte E. Oncogenic Signaling Pathways in Carcinogenesis. J Carcinog 2023;22(1):114-122

which stimulate unchecked cell division, avoid growth inhibitors, withstand cell death, and encourage angiogenesis, the development of new blood vessels to support the expanding tumor. The mitogen-activated protein kinase (MAPK) pathway is one of the main participants in oncogenic signaling. Cancer cells frequently have this pathway hyperactivated, which increases the number of cells that proliferate and survive. Dysregulation of growth factor receptors or mutations in upstream signaling molecules like Ras or Raf can cause aberrant activation of MAPK signaling. The prolonged activation of elements of the MAPK pathway is a major factor in the unchecked proliferation of cancer cells. They are essential performers in the difficult net of molecular results that cause the beginning and development of many kinds of cancer. This change of normal cells into cancer cells results from the start of oncogenic signaling pathways, which resolve the vital procedures of cell invasion, angiogenesis, survival and proliferation. Above the earlier eras, significant progresses have been created to separate the complex network of oncogenic signaling pathways in carcinogenesis. This development has not only extended our knowledge of cancer biology but has also covered the technique for the growth of directed treatments that precisely prevent these pathways. In this thorough analysis, we determination discover the complex web of oncogenic signaling pathways and their essential part in the pathogenesis of cancer. We are investigate the cellular and molecular processes that regulate the stimulation of these pathways, their participation in tumorigenesis, and the therapeutic approaches they offer [3]. These pathways include a sequence of connected signaling forces that control important cellular operations, comprising survival, death, differentiation and cell growth. Dysregulation of these pathways can direct the gaining of cancerous phenotypes, enabling the movement of normal cells to a cancerous state.

Furthermore, cancer is depicted by unrestrained cell propagation and opposition to cell death. Oncogenic signaling pathways perform a vital role in operating these mechanisms. One of the most well-known signaling pathways included in cell production is the Ras-Raf-MEK-ERK pathway. This pathway is stimulated downstream of G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs), and is generally dysregulated in several cancer kinds. Upon stimulation, Ras recruits Raf to plasma membrane, introducing a cascade of phosphorylation actions that eventually lead to ERK kinase stimulation [4]. ERK kinases translocate to the nucleus and phosphorylate transcription aspects, promoting the manifestation of genes which stimulate cell cycle development. The Mitogen-Activated Protein Kinase (MAPK) pathway signifies most considerably investigated oncogenic signaling pathways. It includes a chain of phosphorylation actions linking kinases like RAF, MEK, and ERK, eventually directing to the stimulation of transcription features and variation of gene manifestation. Dysregulation of the Mitogen Activated Protein Kinase (MAPK) pathway is commonly perceived in several cancer types: colorectal cancer, non-small cell lung cancer and melanoma [5]. Another important component in oncogenic signaling is the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of the rapamycin (mTOR) pathway. This route has a role in controlling the metabolism, growth, and survival of cells. Components of this system are frequently found to be mutated or amplified in a variety of malignancies, which results in apoptosis evasion and greater resistance to anti-cancer therapies. In the field of cancer research, targeting the PI3K/Akt/mTOR pathway has shown promise as a therapeutic approach. Signaling is just another complex network that has been linked to the development of cancer. Although Wnt signaling is essential for tissue homeostasis and embryonic development, disruption of this signaling pathway is frequently linked to the onset and spread of cancer. Mutations in essential pathway components, including β-catenin, can cause aberrant Wnt signaling, which can uncontrollably activate target genes involved in cell survival and proliferation. Most remarkably, the tumor suppressor protein p53 protects the genome, coordinating the reactions of cells to injury and stress. The p53 pathway is weakened in many malignancies, either due to upstream signaling anomalies or direct TP53 gene alterations. The loss of functioning p53 promotes genomic instability and cancer growth by enabling cells with damaged DNA to survive and proliferate. Alterations in constituents of this pathway, like RAS and BRAF reduce cells refractory to development inhibitory signs, promoting unrestrained propagation. Another significant pathway in cell propagation is the phosphoinositide 3-kinase (PI3K) Akt-mTOR pathway.

PI3K stimulation directs to the production of phosphatidylinositol, trisphosphate (PIP3), which in turn employs Akt to the plasma membrane. Akt-mTOR is phosphorylated and stimulated through phosphoinositide-reliant kinase 1 (PDK1) and mTOR-complex 2 (mTORC2) [6]. Stimulated Akt endorses cell existence and development by inhibiting proapoptotic aspects and promoting protein amalgamation by mTOR-complex 1 (mTORC1). Dysregulation of PI3K-Akt-mTOR pathway is a frequent aspect of various cancer kinds. Moreover, the Wnt/β-catenin pathway is crucial in controlling cell propagation and survival. In the nonexistence of Wnt ligands, β-catenin is pointed for degradation by a devastation complex. Once Wnt signaling is stimulated, β-catenin is steadied and translocates to the nucleus, wherever it relates with TCF/LEF transcription aspects to endorse the manifestation of genes occupied in cell cycle development [7]. The TP53 signaling pathway is a tumor suppresser pathway commonly deactivated in cancer.

The TP53 gene encodes p53 protein that performs a vital role in controlling the cell cycle and persuading apoptosis in reaction to DNA mutilation. Alterations in the TP53 gene are common in various kinds of cancer, leading to the damage of p53 operation and the dysregulation of downstream signaling pathways. Moreover, The APC signaling pathway is a tumor suppresser gene pathway commonly deactivated in colorectal cancer. The APC gene encodes a protein which controls the Wnt/β-catenin signaling pathway, that performs a significant role in regulating cell propagation and diversity [8]. Alterations in the APC gene are common in colorectal cancer, directing to the dysregulation of the Wnt/β-catenin signaling pathway and the elevation of tumor development.

Additionally, the JAK/STAT signaling pathway is often dysregulated in hematologic tumors. It is stimulated by the binding of cytokines to receptors on the cell exterior, directing to the instigation of downstream signaling cascades that endorse cell development and survival. Alterations in JAK2, that encrypts a tyrosine kinase which controls down-stream signaling, are common in myelo-proliferative neoplasms [9]. The NF-κB (Nuclear Factor-kappa B) signaling pathway is a fundamental intermediary of immunity, inflammation and cell existence. Abnormal NF-κB stimulation is a symbol of various cancer types, comprising colon cancer, breast cancer, and lymphoma. Dysregulated NF-κB signaling helps tumor cell survival, inflammation, and opposition to apoptosis, offering a fertile ground for tumor development [10]. Originally discovered for its function in embryonic development, the Hedgehog signaling system has also been linked to the development of cancer. Medulloblastoma and basal cell carcinoma are two malignancies linked to aberrant Hedgehog signaling activity. Clinical trials and preclinical research have indicated that targeting this route may be a promising therapeutic approach for the treatment of cancer. Apart from these established routes, there is a growing focus on the interaction between cancer cells and the tumor microenvironment. The interaction of immune cells, cancer cells, and extracellular matrix plays a major role in the development of tumors. Immune checkpoint pathways, which include CTLA-4 and PD-1/PD-L1, are essential for regulating the immune system's response to cancer cells.[11] Treatments for cancer that target these immunological checkpoints have transformed the field and produced long-lasting results in a variety of cancer types[12, 13].

Research Objective

In the current report, oncogenic signaling pathways play a vital part in the growth and development of cancer through propagation, cell cycle progression, and apoptosis in both solid tumors and hematologic tumors regulating growth. Dysregulation of these pathways can happen across a series of processes, comprising epigenetic changes, deletions, amplification and mutations. The connection of oncogenic signaling pathways has developed into an important stage in cancer drug development and cancer treatment. Understanding the molecular methods fundamental the dysregulation of these pathways is dangerous for the growth of directed analyses for cancer treatment. As investigation in this area persists to progress, more understandings into the complexities of oncogenic signaling pathways assure to form the upcoming background of cancer prevention and medication.

The research study describes Oncogenic Signalling Pathways in Carcinogenesis. The research paper is divided into five specific chapters: the first section demonstrates the introduction related to the variables. This section also presents the objective of the research study. The second section describes the literature review the third portion describes the methodology. This section describes applications related to the variables. The fourth section present results, and its descriptions include interpretations between them. the last portion summarized overall research study and present some recommendation about Oncogenic Signalling Pathways in Carcinogenesis[14].

Literature review:

Researchers explain that certain non-coding RNAs play a significant role in developing cancer cells. The progression of cancer is mainly associated with the action of long miRNA noncoding RNAs. tumorigenesis is induced through the dysregulation of IncRNAs .under certain conditions the IncRNAs react with miRNAs to regulate the cellular processes for preventing the cancer cell production[15].studies reveal that hyperproliferation of oncogenesis is associated with certain oxidative stressors. reactive oxygen species accumulation results in the progression of tumor cells. cell signaling is detected by ROS for facilitating the tumor cell transformation[16] Studies reveal that research on CRC is made under tumor microenvironments. the alternation in genes causing CRC is determined through the interaction of genes with the environment as well as by the genotypes associated with tumor cells. TME plays a role of pro as well as anti-tumor cells because of their dual nature[17].studies explain that the gene expression role is played prominently through the RBPs [18]. the regulatory role of RBPs is observed in various gene-based regulatory networks. cancer-related functions are associated with the regulatory functioning of RBPs . the oncogenic based signaling regulation is performed by the cell involved in cancer development[19] Studies reveal that the adhesion of the cell to the substrate requires regulation by signaling pathways. without proper cell signaling pathways cell phases anoikis.by resisting the process of anoikis, cancer cell proliferation can be prevented. the singling organelle ,bleb plays a significant role in cell survival and provides resistance against

anoikis[20] Studies reveal that the larynx is a part of the oral cavity. The larynx malignancy causes Laryngeal cancer. the LC causes a lot of risk factors that include obesity as well as HPV. The Epigenetic fluctuations plays a major role in developing LC. To improve the signaling pathway to prevent cancer cell development, the use of miRNAs is made[21]. Studies reveal that bladder cancer is among the most prevalent cancer in males as well as in females. Patient having BC requires proper care.to diagnose and treat the BC various new treatment-based therapeutic approaches have been used in clinical procedures. Using MiRNAs for regulating the functioning of cellular processes holds immense importance.the downregulation and upregulation are shown by MiRNA during the process of epigenetic alternations[22] An individual's vulnerability to carcinogenesis is influenced by lifestyle choices, genetic predisposition, and exposure to carcinogens, among other environmental variables. For example, there is evidence linking certain infections, UV light, and tobacco smoke to a higher chance of developing cancer. Furthermore, genetic abnormalities passed down through families can predispose people to specific cancer types, underscoring the significance of personalized methods in the evaluation and prevention of cancer risk. The development of precision medicine and tailored therapeutics has been made possible by significant insights into the complex mechanisms of carcinogenesis that have been gained through advances in molecular biology and genomics. With the least amount of harm to healthy tissues, these strategies seek to precisely target the molecular anomalies that fuel the spread of cancer. Another innovative approach to treating cancer is immunotherapy, which uses the body's immune system to identify and destroy cancer cells. Studies explain that the signaling [23]pathway plays a prominent role in regulating normal epigenetic functioning. Chemotherapeutic drugs have been developed to inhibit the growth of CSCs. the development of ant-cancer drug targets provides effective treatment against CSC proliferation[24] The molecular landscape of carcinogenesis is influenced by a number of important candidates and signaling pathways. When activated, oncogenes—mutant versions of normal genes involved in cell growth and survival, or proto-oncogenes—promote unchecked cell proliferation. Conversely, tumor suppressor genes serve as the genome's protectors, preventing the growth of cancer by controlling the course of the cell cycle, DNA repair, and apoptosis. These regulatory brakes are released when tumor suppressor genes are mutated or become inactive, which permits cancer cells to proliferate unchecked[25, 26].

Studies show that AHR cells are found among various tissues. These cells are found along with immune cells and are activated by the action of certain microorganisms[27]. The role of serval microbial pathogens is modulated by the actions of AHR.the abnormal functioning of AHR results in immune system disruption that leads to the production of cancer cells[28]. Studies predict that the cell proliferation process involved in cell signaling pathways gets disturbed due to the onset of breast cancer. researchers reveal that lncRNAs play a significantly critical role in maintaining the multiple signaling pathways. The alternations in the functioning of various pathways involved in normal cell proliferation of the breast cell result in the development of breast cancer[29].Studies suggest that cells function through proper regulation of signaling pathways. Any disturbance in the normal functioning of cells results in cancer cell production. The dysregulation of oncogenic transcription factor due to the dysregulation of the fgfr1 pathway results in the BC. Also, the foxq1 factor gets disturbed by the deregulatory functioning of the fgfr1 factor that ultimately results in the production of breast cancer cells[30]. Studies reveal that malignant tumor cells developed in glial tissue result in glioma. The stem cells found in the brain turn into malignant tumor cells, resulting in the onset of glioma. GCSCs are the cells that are involved in the pathogenesis of glioma. Targeting the GCSC ells helps in treating the glioma condition effectively[31].studies claim that membrane receptors play a significant role in defending the specificity of ligand binding sites. Integrins are the membrane receptors involved in determining the signaling properties of domains of cytoplasmic sites.By understating the regulatory role of integrins, it is possible to treat the production of cancer cells. The bidirectional cell signaling pathways are regulated through the treatment approaches for stopping the proliferation of cancer cells[32, 33].

Studies highlight that there are several malignant tumors, but PDAC is the most lethal form of malignant tumor. Certain epigenetic alternation results when the oncogenic signaling is harbored by the PDAC. The chromatin-modifying proteins functioning gets disturbed due to the genetic alternation occurred in PDAC condition[34, 35] Studies claim that circular RNAs are among the cells of single stranded transcripts of RNA that are found in the eukaryotic cells. The functioning of biological process is controlled trough the trough these RNAs[36].studies reveal that the third main cause of cancer relted death is CRC the. The effective treatment against this disorder type is possible through the use of therapeutic measures.

The effective treatment approaches increase the survival of a patient with CRC. cancer stem cells present in CRC condition causes treatment resistance.by targeting the cancer stem cells, the occurrence of CRC can be reduced[37, 38].studies suggest that cervical cancer mostly occurs in women. This cancer type requires effective treatment and strategies to cope with the damage caused by cervical cancer. The oncogenes play a critical role in the proliferation of cancer cells associated with cervical cancer[39].studies reveal that a large number of cancer-

affected people suffer from various other health-related problems. Adopting the proper treatment measure for treating cancer is critical for improving a cancer patient's health. lung cancer is one of the leading causes of death among various cancer types. The changes in the signaling pathway increase the prevalence chances of lung cancer[40].

Studies reveal that in undeveloped countries, a lot of people face health problems. these health problems, if not treated, become severe with time and increase the chances of HPV. the severity of HPV infection causes extreme disease that develops into cervical cancer. For regulating cellular networking, the use of miRNAs is made[41]. Studies highlight the receptor EGFR is involved in cancer cell production. ERBB is another receptor that is involved in the proliferation of stem cells. The signaling pathways involved in stem cell cancer are controlled by the ERBB receptor[42].

Research Methodology:

The research study determines that oncogenic signaling pathways in carcinogenesis this research study based on primary data analysis for determine the research used smart PLS software and generate results.

Descriptive statistical analysis, the correlation coefficient analysis, the smart PLS Algorithm model these are all present overall research study.

Descriptive statistic:

Table 1

Name	No.	Mean	Median	Scale min	Scale max	Standard deviation	Excess kurtosis	Skewness	Cramér-von Mises p value
OS1	0	1.820	2.000	1.000	4.000	0.817	0.178	0.806	0.000
OS2	1	1.480	1.000	1.000	3.000	0.574	-0.414	0.735	0.000
OS3	2	1.640	1.000	1.000	4.000	0.794	1.289	1.252	0.000
OS4	3	1.360	1.000	1.000	3.000	0.520	-0.020	1.036	0.000
CC1	4	1.680	2.000	1.000	3.000	0.676	-0.744	0.507	0.000
CC2	5	1.560	1.000	1.000	4.000	0.697	1.650	1.238	0.000
CC3	6	1.500	1.000	1.000	3.000	0.608	-0.260	0.825	0.000
CC4	7	1.580	2.000	1.000	4.000	0.666	1.980	1.162	0.000

The above result represents that descriptive statistic analysis result describe the average value of mean of each indicator for measuring the Oncogenic Signalling Pathways in Carcinogenesis. The result describes the standard deviation, the skewness values, present probability rates, the minimum value, and maximum values of each variable, including independent also dependent variables. The OS1, OS2, OS3 and OS4 these are all consider as independent variable according to the result its mean values are 1.820, 1.480, 1.540 and 1.360 shows that positive average value of mean. The result also describes the standard deviation rates are 81%, 57%, 79%, and 52% deviate from mean.

According to the result overall minimum value is 1.000 the maximum value is 4.000 the median rate shows 2.000 respectively. The CC1, CC2, CC3 and CC4 these are all consider as dependent variables according to the result its mean values are 1.6800, 1.5600, 1.500 and 1.580 all of them are present positive average value of mean. The standard deviation rates are 69%, 60% and 66% deviate from mean values of each variable. The intricate process known as "carcinogenesis" is what turns healthy cells into cancerous ones, which eventually causes tumors to develop and spread.

The usual regulatory mechanisms governing cell growth, differentiation, and death are disrupted by a succession of genetic and epigenetic modifications that are involved in this complex trip. It is essential to comprehend the mechanisms underlying carcinogenesis in order to develop strategies for cancer detection, prevention, and treatment that work. Carcinogenesis is a process that usually occurs in stages, with the initiation phase being the first. An initiated cell is created during initiation when genetic mutations or changes take place in the DNA of a normal cell.

Numerous things, including exposure to carcinogens like chemicals, radiation, or specific viruses, can result in these changes. Interestingly, not every initial cell goes on to develop cancer, and there are other variables that affect the chance of additional transformation. After initiation, started cells undergo clonal growth during the promotion stage.

Applications

Now that the complexities of oncogenic signalling pathways in carcinogenesis have been clarified, let's investigate the real-world implications of this understanding. Knowing these pathways is more than simply an intellectual exercise; it's a key to many doors in the fields of cancer diagnosis, therapy, and prevention.

Diagnostic Equipment:

• Biomarkers: Specific mutations in oncogenic pathways can be identified and used as biomarkers to identify cancer early.

Checking for these molecular fingerprints makes it possible to detect cancer early on and provide prompt

treatment.

• Genomic Profiling: A patient's tumor can be profiled by knowing the genetic changes in oncogenic pathways. By customizing medicines based on the distinct molecular features of each malignancy, physicians can develop more potent therapeutic approaches.

Specialised Treatments:

• Precision Medicine: The field of precision medicine is made possible by the identification of oncogenic signaling pathways. Small molecule inhibitors and monoclonal antibodies are examples of targeted medicines that can precisely block the aberrant signals that fuel the growth of cancer while causing the least amount of harm to healthy cells.

• Clinical Trials: The creation of new therapeutic medicines is fueled by our understanding of carcinogenic pathways. Patients with tumors caused by certain mutations have hope thanks to clinical trials evaluating these drugs, which are ushering in a new era of specialized therapy.

Predictive Markers:

• Disease Progression: Knowledge of the role oncogenic pathways play in the advancement of cancer offers insights on the disease's capacity for aggression. Clinicians can use this information to design suitable management strategies and to forecast prognoses.

• Reaction to Treatment: A tumor's molecular makeup affects how well it responds to therapy. Understanding oncogenic pathways helps physicians choose the best course of action by helping to anticipate how a cancer may respond to particular medicines.

Preventing Cancer:

• Lifestyle Modifications: Information about oncogenic pathways might help people who are at risk of certain malignancies make better lifestyle choices. Using the molecular knowledge of cancer to target modifiable risk factors, such food and exercise, may help preventative efforts.

• Screening Strategies: Customized monitoring and early detection programs are made possible by the identification of high-risk patients by genetic screening. Frequent surveillance of patients with a genetic susceptibility to particular oncogenic mutations can improve the likelihood of prompt intervention.

Initiatives in Public Health and Education:

• Raising Public Awareness: By educating the public about oncogenic signaling pathways, health-related decisions may be made with more information. Raising awareness can result in prompt medical consultation, proactive health-seeking behaviors, and early symptom detection.

• Genetic Counselling: This type of counseling is beneficial for those who have a family history of malignancies associated with certain oncogenic mutations. People can choose genetic testing and preventative actions with knowledge of the inherited components of cancer risk. To put it simply, there are a lot of uses for our knowledge of oncogenic signaling pathways outside of the lab. They are ubiquitous in the clinical context, impacting cancer prevention, diagnosis, and treatment. More individualized, focused, and potent cancer-fighting strategies are likely in the future as study into the intricacies of these pathways deepens.

Correlation coefficients:

Table 2

	OS1	OS2	OS3	OS4	CC1	CC2	CC3	CC4
CC1	0.258	-0.171	0.046	0.100	1.000	0.000	0.000	0.000
CC2	0.001	-0.072	-0.069	0.216	-0.214	1.000	0.000	0.000
CC3	0.423	-0.000	-0.248	0.190	0.194	0.000	1.000	0.000
CC4	0.045	0.109	0.470	0.263	0.057	-0.096	0.025	1.000
OS1	1.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
OS2	0.099	1.000	0.000	0.000	0.000	0.000	0.000	0.000
OS3	-0.131	-0.016	1.000	0.000	0.000	0.000	0.000	0.000
OS4	0.153	0.225	0.072	1.000	0.000	0.000	0.000	0.000

The above result demonstrates that the correlation coefficient analysis result present CC1 shows a 25% positive correlation with OS1. The CC1 also represent that -0.171 negative correlation in between CC1 and OS2 respectively. The CC2 shows that -0.072, -0.069 and -0.214 negative correlation between them.

Overall result describes that negative and positive correlation between both indicators. The result also presents that OS3 shows -0.131, -0.016, all of them are represent negative interrelation between them.

Carcinogenesis:

Carcinogenesis is a complex process characterized by a multitude of molecular processes. It is the process by which normal cells change into cancer cells through a sequence of genetic and epigenetic changes. There are multiple stages to this complex dance of cellular alterations, including initiation, promotion, progression, and metastasis. Carcinogenesis begins at the beginning phase and is fueled by exposure to substances known as carcinogens, which can cause genetic alterations. These

mutations act as triggers, allowing a cell to start down the dangerous path towards becoming cancerous. Carcinogens can take many different forms, ranging from sun radiation to chemical components in tobacco smoke. These substances have the ability to directly harm DNA or obstruct its repair processes, which can lead to genetic instability. The instructions that control biological operations are encoded in a cell's DNA, which is the blueprint for life. Changes in these instructions due to mutations can cause dysregulation of regular cellular functions.

For example, the removal of the brakes on cell division caused by mutations in tumor suppressor genes, including p53, can result in abnormally high cell proliferation. After surviving the genetic mutation storm, initiated cells move on to the promotion phase, which is when potentially cancerous cells are fostered. Numerous factors, including hormones, ongoing inflammation, and more exposure to carcinogens, have an impact on this stage. After surviving the initiation phase, cells go through additional modifications that provide them a selective advantage and encourage survival and growth.

In the context of cancer promotion, hormones—which typically serve crucial roles in physiological processes—can become double-edged swords. The sinister culmination of carcinogenesis is metastasis, which is the movement of cancer cells from the original tumor to other parts of the body, where they give rise to new tumors. At this point, cancer takes on a more menacing aspect, evolving from a localized concern to a systemic threat. The metastatic process is a convoluted series of circumstances.

Cancer cells develop the capacity to infiltrate lymphatic or blood vessels, allowing them to travel through the circulatory system and arrive at distant organs. When they reach these unfamiliar locations, they have to adjust to the local conditions and start the difficult process of growing new tumors. There are numerous pathways that promote metastasis. As these rogue cells move through the bloodstream, they can avoid identification and death thanks to immune system evasion, a hallmark of cancer. Additionally, the success of metastatic colonization depends on the complex interactions that occur between cancer cells and the microenvironment of distant organs.

Smart PLS Algorithm Model:



Figure 1

The above model describes that smart PLS Algorithm model in between OS and CC foe determine the Oncogenic signaling Pathways in Carcinogenesis. According to the result, OS shows 0.758, -0.065, -0.705, and 0.202 rates of each factor related to the Oncogenic Signaling Pathways in Carcinogenesis. Model describes that OS shows a 55% significant relation with CC. Its rates of each factor are 42%, 13%, 85%, and 38%, respectively.

Conclusion:

Uncontrolled cell proliferation and expansion characterize cancer, a complex and varied group of disorders. Carcinogenic signaling pathways are essential for the development and spread of cancer. An overview of the major signaling pathways connected to carcinogenesis is given in this article, with particular attention to the Wnt, PI3K/AKT/mTOR, and Ras pathways. Ras gene mutations cause abnormal cell proliferation, whereas the PI3K/AKT/mTOR pathway is dysregulated to support cell growth and survival. A common alteration in cancer is the Wnt pathway, which is essential for proper development and contributes to uncontrolled cell proliferation. These pathways illustrate the complex nature of cancer biology by representing linked signaling networks. Understanding these pathways better has allowed for the creation of tailored therapeutics, which raises the prospect of more

individualized and successful cancer treatments. Untangling the complexity of oncogenic signaling pathways remains a major area of scientific interest since it offers insights that influence cancer diagnosis and treatment in the future. In summary, deciphering oncogenic signaling pathways is essential to comprehending the intricate processes that underlie the emergence of cancer. Key pathways including Wnt, PI3K/AKT/mTOR, and Ras may become dysregulated, which can lead to uncontrollably fast cell division, apoptosis avoidance, and other cancer-related traits. Research progresses in identifying certain genetic mutations and molecular changes linked to these pathways, offering important information for focused treatments. Treatment for some cancers may be improved by the creation of tailored medications that obstruct these pathways. Our growing understanding of oncogenic signaling creates opportunities for more accurate diagnosis and individualized therapy plans. The complex web of signaling cascades involved in the development of cancer highlights the necessity of an all-encompassing strategy for cancer research and treatment advancement.

References:

1. A. A. Farooqi, M. De La Roche, M. B. Djamgoz, and Z. H. Siddik, "Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights," in *Seminars in cancer biology*, 2019, vol. 58: Elsevier, pp. 65-79.
2. F. Sanchez-Vega *et al.*, "Oncogenic signaling pathways in the cancer genome atlas," *Cell,* vol. 173, no. 2, pp. 321-337. e10, 2018.
3. A. Q. Khan *et al.*, "RAS-mediated oncogenic signaling pathways in human malignancies," in *Seminars in cancer biology*, 2019, vol. 54: Elsevier, pp. 1-13.
4. S. Zada *et al.*, "Cross talk between autophagy and oncogenic signaling pathways and implications for cancer therapy," *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer,* vol. 1876, no. 1, p. 188565, 2021.
5. S. Gc, S. L. Bellis, and A. B. Hjelmeland, "ST6Gal1: Oncogenic signaling pathways and targets," *Frontiers in Molecular Biosciences,* vol. 9, p. 962908, 2022.
6. J. Lu, P. Wilfred, D. Korbie, and M. Trau, "Regulation of canonical oncogenic signaling pathways in cancer via DNA methylation," *Cancers,* vol. 12, no. 11, p. 3199, 2020.
7. B. Wu *et al.*, "Long noncoding RNA H19: a novel therapeutic target emerging in oncology via regulating oncogenic signaling pathways," *Frontiers in Cell and Developmental Biology,* vol. 9, p. 796740, 2021.
8. A. S. Dhillon, S. Hagan, O. Rath, and W. Kolch, "MAP kinase signalling pathways in cancer," *Oncogene,* vol. 26, no. 22, pp. 3279-3290, 2007.
9. F. Li *et al.*, "A comprehensive overview of oncogenic pathways in human cancer," *Briefings in Bioinformatics,* vol. 21, no. 3, pp. 957-969, 2020.
10. L. Xia *et al.*, "Role of the NFκB-signaling pathway in cancer," *OncoTargets and therapy,* pp. 2063-2073, 2018.
11. R. Dale, N. Kato, and B. Wischusen, "Modeling and analysis of the firefly luciferase reaction and the G-protein coupled receptor signaling pathway with ordinary differential equations increases self confidence in mathematical cell biology for novice graduate students," *Letters in Biomathematics,* vol. 7, no. 1, pp. 3–13-3–13, 2020.
12. E. A. McCaman, "Encouraging Innovation in Preventive Health Technology: A Spotlight on Women's Health," *Journal of Commercial Biotechnology,* vol. 22, no. 1, 2016.
13. K. A. Mowafy, M. Soliman, A. M. Hammoda, and R. M. Soliman, "Bilateral lower limb disabling claudication in a young man: a case of Mönckeberg's arteriosclerosis," *Vasc Endovasc Review,* vol. 2, no. 1, pp. 48-52, 2019.
14. M. BILECENOGLU and T. ÇELIK, "Easternmost occurrence of Didogobius schlieweni Miller, 1993 (Gobiidae) in the Mediterranean Sea," *FishTaxa,* vol. 19, pp. 1-4, 2021.
15. F. Malakoti *et al.*, "Long noncoding RNA SNHG7-miRNA-mRNA axes crosstalk with oncogenic signaling pathways in human cancers," *Chemical Biology & Drug Design,* vol. 101, no. 5, pp. 1151-1161, 2023.
16. W. Zeng, X. Long, P. S. Liu, and X. Xie, "The interplay of oncogenic signaling, oxidative stress and ferroptosis in cancer," *International Journal of Cancer,* 2023.
17. S. Ben Hamouda and K. Essafi-Benkhadir, "Interplay between Signaling Pathways and Tumor Microenvironment Components: A Paradoxical Role in Colorectal Cancer," *International Journal of Molecular Sciences,* vol. 24, no. 6, p. 5600, 2023.
18. L. Cano, Á. Piza, and F. Farfán, "HIGH INTENSITY INTERVAL TRAINING IN YOUNG RUGBY PLAYERS FROM ARGENTINA," *Revista Internacional de Medicina y Ciencias de la Actividad Física y del Deporte,* vol. 20, no. 80, 2020.
19. W. Zhou *et al.*, "Single-cell RNA binding protein regulatory network analyses reveal oncogenic HNRNPK-MYC signalling pathway in cancer," *Communications Biology,* vol. 6, no. 1, p. 82, 2023.
20. A. D. Weems *et al.*, "Blebs promote cell survival by assembling oncogenic signalling hubs," *Nature,* vol. 615, no. 7952, pp. 517-525, 2023.
21. M. Hegazy *et al.*, "The role of miRNAs in laryngeal cancer pathogenesis and therapeutic resistance-A focus on signaling pathways interplay," *Pathology-Research and Practice,* p. 154510, 2023.
22. H. A. El-Mahdy *et al.*, "miRNAs role in bladder cancer pathogenesis and targeted therapy: Signaling pathways interplay-A review," *Pathology-Research and Practice,* p. 154316, 2023.
23. E. ÇIÇEK, D. AVŞAR, H. YELDAN, and M. MANAŞIRLI, "Otoliths atlas of 77 fish species from the Iskenderun Bay, Northeastern Mediterranean Sea," *Fishtaxa-Journal of Fish Taxonomy,* no. 19, 2021.
24. S. Bhal and C. N. Kundu, "Targeting crosstalk of signaling pathways in cancer stem cells: A promising approach for development of novel anti-cancer therapeutics," *Medical Oncology,* vol. 40, no. 2, p. 82, 2023.
25. T. Jambulingam, C. Schellhorn, and R. Sharma, "Using a rasch model to rank big pharmaceutical firms by financial performance," *Journal of Commercial Biotechnology,* vol. 22, no. 1, 2016.
26. J. Coughlan, T. J. Kiernan, and S. Arnous, "Alternative access for transcatheter aortic valve implantation: current evidence and future directions," *Vascular & Endovascular Review,* vol. 2, no. 1, pp. 23-7, 2019.
27. M. Igoe *et al.*, "A Discrete Age Structured Model of Hantavirus in a Rodent Reservoir in Paraguay," *Letters in Biomathematics,* vol. 7, no. 1, pp. 127–142-127–142, 2020.
28. J. Hu, Y. Ding, W. Liu, and S. Liu, "When AHR signaling pathways meet viral infections," *Cell Communication and*

Signaling, vol. 21, no. 1, p. 42, 2023.
29. R. Thapa *et al.*, "Unveiling the connection: long-chain non-coding RNAs and critical signaling pathways in breast cancer," *Pathology-Research and Practice,* p. 154736, 2023.
30. Y. Lin *et al.*, "The fgfr1 signaling pathway upregulates the oncogenic transcription factor foxq1 to promote breast cancer cell growth," *International Journal of Biological Sciences,* vol. 19, no. 3, p. 744, 2023.
31. A. Nasrolahi *et al.*, "Signaling pathways governing glioma cancer stem cells behavior," *Cellular Signalling,* vol. 101, p. 110493, 2023.
32. S. Li, C. Sampson, C. Liu, H.-l. Piao, and H.-X. Liu, "Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities," *Cell Communication and Signaling,* vol. 21, no. 1, p. 266, 2023.
33. P. García-Fernández, J. Guodemar-Pérez, M. Ruiz-López, E. Rodríguez-López, A. García-Heras, and J. Hervás-Pérez, "Epidemiology of injuries in professional and amateur Spanish paddle players," *Revista Internacional de Medicina y Ciencias de la Actividad Física y del Deporte,* vol. 19, no. 76, 2019.
34. R. Agrawal and K. N. Natarajan, "Oncogenic signaling pathways in pancreatic ductal adenocarcinoma," *Advances in Cancer Research,* vol. 159, pp. 251-283, 2023.
35. A. Ramos-Jiménez, R. P. Hernández-Torres, R. Urquidez-Romero, A. Wall-Medrano, and R. Villalobos-Molina, "Body image satisfaction as a physical activity indicator in university students," *American Journal of Health Behavior,* vol. 41, no. 5, pp. 599-607, 2017.
36. F. Hu, Y. Peng, X. Fan, X. Zhang, and Z. Jin, "Circular RNAs: implications of signaling pathways and bioinformatics in human cancer," *Cancer Biology & Medicine,* vol. 20, no. 2, p. 104, 2023.
37. N. Ebrahimi *et al.*, "Cancer stem cells in colorectal cancer: Signaling pathways involved in stemness and therapy resistance," *Critical Reviews in Oncology/Hematology,* p. 103920, 2023.
38. F. N. Amiri, Z. Basirat, S. Omidvar, M. Sharbatdaran, K. H. Tilaki, and M. Pouramir, "Comparison of the serum iron, ferritin levels and total iron-binding capacity between pregnant women with and without gestational diabetes," *Journal of natural science, biology, and medicine,* vol. 4, no. 2, p. 302, 2013.
39. K. A. Tadlaoui and M. M. Ennaji, "The molecular mechanism of novel oncogenes dysregulating signaling pathways associated with cervical carcinoma," in *Immunological Implications and Molecular Diagnostics of Genitourinary Cancer*: Elsevier, 2023, pp. 19-31.
40. A. S. Nair, A. P. Jayan, K. Anandu, V. Saiprabha, and L. K. Pappachen, "Unraveling the prevalence of various signalling pathways in non-small-cell lung cancer: a review," *Molecular and Cellular Biochemistry,* pp. 1-16, 2023.
41. A. S. Doghish *et al.*, "miRNAs role in cervical cancer pathogenesis and targeted therapy: Signaling pathways interplay," *Pathology-Research and Practice,* p. 154386, 2023.
42. G. Hassan and M. Seno, "ERBB Signaling Pathway in Cancer Stem Cells," in *Cancer Stem Cell Markers and Related Network Pathways*: Springer, 2023, pp. 65-81.